• Abbott to commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia and Middle East and Africa
• mAbxience Holdings S.L (a Fresenius Kabi majority-owned group and partial ownership from Insud Pharma) to develop, manufacture and supply the biosimilar molecules
• First molecules expected to launch as early as 2025, offering new treatment options that leverage the latest in scientific breakthroughs for people in emerging markets

mAbxience will manufacture the biosimilars in its state-of-the art and Good Manufacturing Practices (GMP)-approved facilities in Spain and Argentina. Additionally, mAbxience will be responsible for achieving the clinical milestones for some of the molecules still undergoing development.

This collaboration with Abbott enhances mAbxience’s global presence, especially in emerging countries. It also builds upon our existing collaboration with Abbott, which began in Latin America in 2018. Under that initial agreement, we enabled Abbott to provide treatment options with two of our cutting-edge oncology biosimilars in several countries, including Colombia, Chile, Peru, and Central America.

“Fresenius Kabi develops its Biopharma business consistently and in various ways. This agreement is another great step in gaining traction in the important out-licensing biosimilars business,” said Dr. Michael Schoenhofen, President Biopharmaceuticals Fresenius Kabi. “The hereby enhanced global availability of upcoming, state-of-the-art biosimilar products will benefit patients, health systems, and our partners in the regions in line with our Vision 2026 strategy.”

“Collaborating with Abbott’s medicines business is a key strategic step to help bring our biosimilars into the hands of more people who need them. Abbott shares a common vision of making high-quality medicines available so that healthcare systems can have cost-effective treatment options, with an opportunity for more people around the world to get healthier,” said Emmanuelle Lepine, Chief Executive Officer, mAbxience. “This new agreement supports our strategy of becoming a leading global player within the biosimilar space.”

“The expanded collaboration with mAbxience will complement our existing branded generic medicines portfolio with state-of-the-art biosimilars,” said Daniel Salvadori, executive vice president and group president, Established Pharmaceuticals and Nutritional Products, Abbott. “With our large footprint in emerging countries and our commitment to put access and affordability at the center of what we do, this strategic collaboration will help more people in more places have access to affordable biosimilar medicines.”

With worldwide population aging and changing lifestyles, non-communicable diseases such as cancer are on the rise[1]. For people in emerging countries, access to care is often not optimal due to physical challenges in accessing a doctor – especially in rural areas – and limitations in standard of care, as the latest innovations may not be available. Lacking access to treatment options and care is one of the reasons why people in emerging countries are much more likely to die from these diseases than people in wealthier countries.[2] More than three-quarters of all deaths worldwide from chronic diseases happen in emerging countries. In Brazil and Mexico, up to 40 percent of cancer patients who may benefit from biologics do not receive the therapy they need.[3]

This collaboration will commercialize biosimilars in select key emerging markets. It will help introduce life-saving treatments in key oncology, women’s health and respiratory diseases for the first time in some countries, at a fraction of the cost of originator biologics, making it more accessible and affordable for healthcare systems in these countries